Lenalidomide, Bortezomib, and Dexamethasone (RVD) Regimen for Multiple Myeloma.

about

Lenalidomide, Bortezomib, and Dexamethasone (RVD) Regimen for Multiple Myeloma.

Item

http://www.wikidata.org/entity/Q38970962

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

Lenalidomide, Bortezomib, and Dexamethasone (RVD) Regimen for Multiple Myeloma.

@en

type

Item

label

Lenalidomide, Bortezomib, and Dexamethasone (RVD) Regimen for Multiple Myeloma.

@en

prefLabel

Lenalidomide, Bortezomib, and Dexamethasone (RVD) Regimen for Multiple Myeloma.

@en

P1476

Lenalidomide, Bortezomib, and Dexamethasone (RVD) Regimen for Multiple Myeloma.

@en

P2093

Alexandra P Punke

http://www.w3.org/2001/XMLSchema#string

Dominic A Solimando

http://www.w3.org/2001/XMLSchema#string

J Aubrey Waddell

http://www.w3.org/2001/XMLSchema#string

P2860

Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma.

Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study.

A phase 2 trial of lenalidomide, bortezomib, and dexamethasone in patients with relapsed and relapsed/refractory myeloma

Front-line transplantation program with lenalidomide, bortezomib, and dexamethasone combination as induction and consolidation followed by lenalidomide maintenance in patients with multiple myeloma: a phase II study by the Intergroupe Francophone du

Antiemetics: American Society of Clinical Oncology clinical practice guideline update.

Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma.

Randomized phase III trial of consolidation therapy with bortezomib-lenalidomide-Dexamethasone (VRd) vs bortezomib-dexamethasone (Vd) for patients with multiple myeloma who have completed a dexamethasone based induction regimen.

Pharmacokinetics and safety of bortezomib in patients with advanced malignancies and varying degrees of liver dysfunction: phase I NCI Organ Dysfunction Working Group Study NCI-6432.

Analysis of decision making at a multidisciplinary head and neck tumor board incorporating evidence-based National Cancer Comprehensive Network (NCCN) guidelines.

Treatment of patients with relapsed/refractory multiple myeloma with lenalidomide and dexamethasone with or without bortezomib: prospective evaluation of the impact of cytogenetic abnormalities and of previous therapies.

P304

27-32

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1310/HPJ5201-27

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28179738

http://www.w3.org/2001/XMLSchema#string

P921

dexamethasone

P932

5278911

http://www.w3.org/2001/XMLSchema#string